10-K: PetVivo Holdings Reports Reduced Losses Amidst Strategic Distribution Shifts and Capital Infusion

PetVivo Holdings, Inc. announced a significant reduction in its net loss for fiscal year 2025, driven by increased product sales and decreased operating expenses, while securing a substantial Series B Preferred Stock offering to bolster future operations despite ongoing going concern doubts and internal control deficiencies.

Summary

• Net loss for fiscal year 2025 decreased to $8,399,166, a notable improvement from $10,955,295 in fiscal year 2024.
• Revenues increased to $1,132,533 in fiscal 2025, up from $968,706 in fiscal 2024, primarily due to new distribution partnerships and the VetStem licensing agreement.
• Sales of Spryng product to distributors accounted for $956,159 in fiscal 2025 and $731,813 in fiscal 2024.
• Sales of Spryng product directly to veterinary clinics were $176,374 in fiscal 2025 and $236,893 in fiscal 2024.
• Operating expenses decreased to $9,050,575 in fiscal 2025 from $11,488,223 in fiscal 2024, mainly due to reduced general and administrative and sales and marketing expenses.
• General and administrative expenses decreased to $4,823,230 in fiscal 2025 from $6,693,186 in fiscal 2024, attributed to decreased legal expenses and reduced investor relations consulting fees.
• Sales and marketing expenses decreased to $2,644,095 in fiscal 2025 from $3,399,666 in fiscal 2024, due to the termination of an expensive marketing agency relationship and reduced trade show participation.
• Research and development expenses increased to $1,583,250 in fiscal 2025 from $1,395,371 in fiscal 2024, related to clinical studies and efforts supporting Spryng's launch.
• Cash and cash equivalents as of March 31, 2025, were approximately $228,000, an increase from $87,403 as of March 31, 2024.
• The company had a working capital deficit of $320,709 as of March 31, 2024, which improved to a working capital of $1,591,212 as of March 31, 2025.
• An investor subscribed to a $5 million Series B Preferred Stock offering, with $600,000 received by March 31, 2025, and the remaining $4.4 million received in May and June 2025.
• The company's internal control over financial reporting was not effective as of March 31, 2025, due to a material audit adjustment for derivative liabilities and warrant discount with convertible notes.
• The company's common stock and warrants were delisted from Nasdaq and approved for trading on the OTCQB market as of July 26, 2024.

Sentiment

Score: 3

Explanation: While the company reduced its net loss and increased revenue, the persistent 'going concern' doubt, extremely limited cash runway, delisting from Nasdaq, and ineffective internal controls indicate significant underlying financial and operational challenges. The capital raise provides a temporary reprieve but does not fundamentally resolve the long-term viability concerns without sustained profitability.

Positives

• Net loss significantly decreased by approximately $2.5 million in fiscal 2025 compared to fiscal 2024, indicating improved financial performance.
• Total revenues increased by 16.9% in fiscal 2025, driven by new distribution partnerships with Vedco and Clipper Distributing, and the exclusive licensing agreement with VetStem.
• Operating expenses decreased substantially, primarily due to reduced general and administrative and sales and marketing costs, reflecting cost management efforts.
• Secured a $5 million Series B Preferred Stock offering, with $4.4 million received post-fiscal year end, providing crucial capital for ongoing operations and business expansion.
• Spryng, the lead product, is classified as a veterinary medical device by the FDA, not requiring pre-market approval, which streamlines commercialization.
• Spryng has shown long-lasting multi-month improvement in lameness in case studies for dogs and horses, with many canines able to discontinue NSAID use, suggesting strong product efficacy and safety profile.
• The company has a pipeline of 17 therapeutic devices for both veterinary and human clinical applications, protected by 12 patents and 6 proprietary trade secrets, indicating strong intellectual property.
• A second ISO cleanroom manufacturing facility is expected to be operational later this year, which will minimize supply risks and allow for continued scaling of production capacity.

Negatives

• The company incurred a net loss of $8,399,166 in fiscal 2025 and has an accumulated deficit of $91,198,490 as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents of approximately $228,000 as of March 31, 2025, are anticipated to satisfy operational and capital requirements for only the next one month, necessitating further capital raises.
• The company's common stock and warrants were delisted from Nasdaq and now trade on the OTCQB market, which can negatively impact liquidity and investor perception.
• Internal control over financial reporting was deemed not effective as of March 31, 2025, due to a material audit adjustment for derivative liabilities and warrant discount, indicating a material weakness.
• Mutually terminated non-exclusive distribution agreements with MWI (March 2025) and Covetrus (February 2025), requiring the company to establish new sales channels.
• The company has a limited operating history and did not begin generating notable revenues from Spryng until the second quarter of fiscal 2023, making business prospects speculative.
• Reliance on third parties for raw materials and clinical studies introduces supply chain and study completion risks.

Risks

• Failure to meet continued listing requirements of The Nasdaq Capital Market has resulted in delisting of securities to OTCQB, potentially impacting liquidity and investor interest.
• Substantial accumulated losses and recurring negative cash flows from operations raise substantial doubt about the company's ability to continue as a going concern.
• Inability to obtain sufficient funding in the future may force the company to materially reduce or discontinue business operations.
• Limited operating history makes evaluation of business prospects difficult and speculative.
• Substantial dependence on the success of Spryng; failure to achieve market acceptance would significantly harm the company.
• Significant competition from major pharmaceutical, biotechnology, and specialty animal health companies with substantially more resources.
• Reliance on third parties to produce raw materials and conduct studies introduces dependency and potential supply/delay risks.
• Rapid commercial growth of Spryng may not be effectively managed, straining management and operational resources.
• Loss of distribution agreements with key partners (MWI, Covetrus terminated; Vedco, Clipper new) could adversely affect revenues and profitability.
• Insufficient or inadequate sales and marketing programs may prevent commercial success of Spryng.
• Damage to reputation or brand due to unsuccessful marketing, product quality issues, or product liability claims.
• Failure to attract and retain qualified management and key scientific personnel could hinder product commercialization and development.
• Natural disasters and other events beyond control could adversely affect operations.
• Ineffective manufacturing and supply chain management could increase operating costs and impact product availability.
• Failure to protect intellectual property (patents, trademarks, trade secrets) could harm competitive position or lead to costly litigation.
• Exposure to intellectual property infringement claims from third parties could result in substantial damages and diversion of management attention.
• Inability to obtain required regulatory approvals for future products timely or at all could delay or prevent commercialization.
• Failure of key information technology systems, networks, or processes may harm business operations.
• Concentrated ownership and control by management (approximately 27% of outstanding common stock) could adversely affect stock perception and delay change of control.
• High volatility of common stock market price due to factors like limited public float, lack of analyst coverage, and overall market fluctuations.
• Potential classification as a 'penny stock' in the future, making securities more difficult to resell.
• Failure to comply with Section 404 of the Sarbanes-Oxley Act regarding internal controls over financial reporting could harm business and stock price.
• No anticipated dividends on common stock for the foreseeable future, as earnings will be retained for business expansion.
• Elimination of monetary liability against directors and executive officers under Nevada law and indemnification rights could result in substantial expenditures.
• Anti-takeover effects in Articles of Incorporation, Bylaws, and Nevada law could discourage or delay changes in control.

Future Outlook

The company anticipates increasing commercialization efforts for Spryng in the United States through sales representatives, clinical studies, and market awareness. It plans to initiate additional third-party studies for Spryng in canine and equine patients and expects to expend resources to advance and improve manufacturing systems for Spryng to increase product volume and efficiency. Research and testing will also be conducted to identify and determine the next commercial product(s), including a Spryng formulation for navicular disease in horses. Revenues from the exclusive licensing agreement with VetStem, Inc. for Precise PRP are expected in fiscal year 2026. The company expects to continue raising additional capital through the sale of securities to fund business expansion.

Management Comments

• "We anticipate that we will be adequate to satisfy operational and capital requirements for the next one (1) month."
• "We expect to continue to incur losses until such time, if ever, as we succeed in significantly increasing our revenues and cash flow beyond what is necessary to fund our ongoing operations and pay our obligations as they become due."
• "We believe that the increased revenues and margins provided by Spryng will accelerate its adoption rate and propel it forward as the standard of care for canine and equine lameness related to or due to synovial joint issues."
• "The decrease [in operating expenses] is primarily due to decreased legal expenses as our corporate/secretary duties have been absorbed by our internal general counsel. The decrease is also attributed to reduced investor relations consulting fees."
• "The decrease [in sales and marketing expenses] is primarily due to the termination of an expensive marketing agency relationship and reduced trade show participation."
• "Management has evaluated the effectiveness of the company's Internal Control Over Financial Reporting (ICFR) and, due to the material weakness, management has concluded that ICFR was not effective as of the end of the fiscal year ending March 31, 2025. The company plans on tightening the ICFR controls moving forward and will be accounting for derivative liabilities and warrant discount."

Industry Context

The animal health market is a strong component of the U.S. economy, showing resilience to economic cycles, with the veterinary sector being an attractive area due to its growth and lack of reimbursement risk. Pet ownership in the U.S. reached record levels in 2022, with 70% of households owning a pet, including 69 million dogs and 7.2 million horses. Osteoarthritis affects approximately 14 million dogs and 1.1 million horses in the U.S., representing a significant market opportunity within the $11 billion companion animal veterinary care and product sales market. Current treatments for osteoarthritis, such as NSAIDs, primarily address symptoms and carry side effect risks, creating a demand for alternative solutions like Spryng that address the underlying cause with minimal adverse effects. The industry relies heavily on a few pre-eminent national distributors (Covetrus, Patterson, MWI), and the company's strategy to diversify sales channels through new partnerships (Vedco, Clipper) is a response to the competitive landscape and the need to replace lost prescription revenues at veterinary practices.

Comparison to Industry Standards

• Spryng is positioned as an alternative to traditional osteoarthritis treatments like NSAIDs, steroid, and hyaluronic acid injections, claiming to address the affliction's cause rather than just symptoms, with minimal adverse side effects, unlike NSAIDs which can cause gastrointestinal, kidney, and liver damage.
• A single injection of Spryng is approximately $600 to $900 per joint and typically lasts for at least 12 months, which the company believes makes it an effective and economical solution compared to other treatments that may be slow-acting or short-lasting.
• The company's product pipeline, derived from biomaterials initially developed for human biomedical applications, aims to leverage existing investments for capital and time-efficient commercialization in the veterinary market, a strategy that could offer a competitive advantage by reducing development costs and time-to-market compared to companies developing products solely for animal use.
• The company's manufacturing in an ISO 7 certified clean room using a patented and scalable self-assembly production process is a standard for quality and efficiency, with the planned second facility further enhancing supply chain resilience, a critical factor in the medical device industry.
• The company faces significant competition from large animal health companies such as Zoetis, Inc., Merck Animal Health, Merial, Elanco, Bayer Animal Health, Novartis Animal Health, Boehringer Ingelheim Animal Health, Virbac Group, Ceva Animal Health, Vetoquinol, and Dechra Pharmaceuticals PLC, most of whom have substantially more financial, technical, and personnel resources, as well as established brands and experience in product development, production, regulation, and commercialization.

Management Changes

Corporate Governance

Legal Proceedings

• David Masters, a former employee, board member, and consultant, threatened to file suit against the company to recover in excess of $2 million related to allegations of promised additional compensation, shares, warrants, and future employment. This was resolved through a mediated settlement agreement for a one-time payment of $180,000, which was paid in October 2023.

Related Party Transactions

• David B. Masters, a former director, had debt settlement agreements and a note conversion agreement with the company. His promissory note of $195,000 (accrued salary) was converted into 43,556 units (common stock and warrants) in August 2021. A settlement payment of $180,000 was made to him in October 2023 to resolve threatened litigation.
• John Lai, CEO and President, had 254,018 shares of common stock held in escrow, which were released to him on August 13, 2021, upon the company obtaining $5 million in equity financing and listing on Nasdaq. In May 2021, Mr. Lai converted 42,188 warrants into 36,915 shares of common stock on a cashless basis. From March 1, 2023, through August 31, 2023, Mr. Lai received his salary payments in shares of common stock (60,600 shares) in lieu of cash.
• In December 2023, options to purchase 195,700 shares of common stock were granted to the Board of Directors for their compensation.
• In October 2024, 240,000 shares of common stock were issued to executive officers in lieu of compensation, valued at $132,000. An executive officer returned 25,000 shares for cancellation.
• In December 2024, 375,000 shares were issued to executive officers for performance services, valued at $150,750. Additionally, 121,808 shares were issued to executive officers for conversion of accrued bonuses, valued at $50,000.
• In March 2025, 225,000 shares were issued to executive officers for performance services, valued at $156,250. Also, 68,628 shares were issued to executive officers for conversion of accrued bonuses, valued at $35,000.
• In March 2025, 150,072 shares were issued to employees and Board Directors for a stock option buyout program, valued at $72,808.
• In February 2025, 20,000 shares were issued to a Board Director for consulting services, valued at $10,800.
• In May and June 2025 (subsequent event), three company Directors collectively entered into three short-term notes in an aggregate amount of $12,000 with an annual interest rate of 10%.

Stakeholder Impact

• **Shareholders:** Face significant risk due to the company's ongoing net losses, accumulated deficit, and the 'going concern' doubt. The delisting from Nasdaq to OTCQB may reduce liquidity and investor interest. Dilution from ongoing capital raises (common stock, preferred stock, convertible notes, warrants) is a continuous concern. The stock option buyout program and stock awards to management and directors could be viewed as beneficial for retention but also as dilutive.
• **Employees:** Compensation includes stock awards and options, aligning their interests with company performance. However, the company's financial instability and 'going concern' warning could create job insecurity. The termination of the COO position indicates potential restructuring or efficiency drives.
• **Customers (Veterinarians & Pet Owners):** The company's lead product, Spryng, offers a promising alternative for osteoarthritis treatment in animals, potentially improving animal welfare. New distribution partnerships aim to increase product availability. The exclusive licensing agreement for Precise PRP expands product offerings.
• **Suppliers:** The company's reliance on third parties for raw materials and clinical studies means their business is tied to the company's operational continuity. The company's liquidity issues could pose payment risks to suppliers.
• **Creditors:** The company has significant notes payable and convertible notes, and the 'going concern' warning indicates a heightened risk for creditors regarding repayment. The recent capital raise provides some short-term relief but long-term solvency remains a concern.

Next Steps

• Increase commercialization efforts of Spryng in the United States through sales representatives, clinical studies, and market awareness.
• Initiate additional third-party studies related to the use of Spryng for the treatment of osteoarthritis in canine and equine patients.
• Advance and improve manufacturing systems for Spryng to increase product volume and overall efficiency.
• Conduct research and testing on existing Spryng formulation and other variations to identify and determine next commercial product(s), including for navicular disease in horses.
• Tighten Internal Control Over Financial Reporting (ICFR) controls and improve accounting for derivative liabilities and warrant discount.
• Continue to raise additional capital through the sale of securities to fund business expansion.

Key Dates

Recommendation

Keywords

PetVivo Holdings, Spryng, OsteoCushion Technology, Veterinary Medical Device, Osteoarthritis, Animal Health, Biomedical Device, SEC Filing, 10-K, Financial Results, Nasdaq Delisting, OTCQB, Capital Raise, Distribution Agreements, Intellectual Property, Corporate Governance, Internal Controls, Going Concern, Canine, Equine, Platelet-Rich Plasma, VetStem, Dermal Filler, Cardiovascular Devices, Drug Delivery, Orthopedic Devices